openPR Logo
Press release

Filgrastim Biosimilars Global Market to Observe Highest Growth of $1.66 Billion with an Excellent CAGR of 10.7% by 2028 | Sandoz Pty Ltd., Apotex Pty Ltd., Mylan, Lupin Limited, Biocon Biologics

07-18-2024 07:45 AM CET | Health & Medicine

Press release from: The Business research company

Filgrastim Biosimilars Market

Filgrastim Biosimilars Market

"The new report published by The Business Research Company, titled Filgrastim Biosimilars Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the filgrastim biosimilars market size has grown strongly in recent years. It will grow from $1.02 billion in 2023 to $1.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The filgrastim biosimilars market size is expected to see rapid growth in the next few years. It will grow to $1.66 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

Neutropenia Prevalence Drives Growth In The Filgrastim Biosimilar Market
The increasing prevalence of neutropenia is expected to propel the growth of the filgrastim biosimilar market going forward. Neutropenia refers to a condition where the body does not have enough neutrophils, which are an important type of white blood cell that fights infections. Filgrastim biosimilars work by stimulating the production of neutrophils in the bone marrow, which increases the neutrophil count and helps fight infections. For instance, in August 2022, according to the National Center for Biotechnology Information, a US-based database for biomedical literature, the prevalence of neutropenia was 0.38% among Mexican-Americans, 0.79% among whites, and 4.5% among black participants. Thus, the increasing prevalence of neutropenia is driving the growth of the filgrastim biosimilar market.

Amneal Pharmaceuticals' Fylnetra Marks A New Era Of Accessible Healthcare With Recombinant Dna Technology
Major companies operating in the filgrastim biosimilar market are developing innovative products with advanced technologies such as recombinant DNA technology to produce biosimilars. Recombinant DNA technology is a process that involves the creation of hybrid or chimeric DNA by inserting a foreign sequence into the DNA of an organism. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen's NEULASTA, in the United States indicated for the treatment and prevention of febrile neutropenia. It promotes the expansion and specialization of neutrophils originating from dedicated precursor cells, triggers their maturation, and improves the viability and efficiency of fully developed neutrophils, leading to dosage-dependent rises in neutrophil counts. The launch of Fylnetra contributes to the next wave of affordable medicines and drives access across patients, providers, and payors.

The filgrastim biosimilars market covered in this report is segmented -
1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization
2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=4016&type=discount

Major companies operating in the filgrastim biosimilars market report are Teva Pharmaceutical Industries Ltd, Novartis International AG, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy's Laboratories, Pfizer, Cadila Healthcare Ltd, Abbott Laboratories, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Apotex Pty Ltd, Mylan, Kyowa Kirin Co. Ltd, Lupin Limited, Biocon Biologics, Coherus Biosciences Inc., North China Pharmaceutical Corporation, Tonghua Dongbaoare, Beijing SL Pharmaceutical, Mochida Pharmaceutical, Fuji Pharma, Amgen (Europe) GmbH, Napp Pharmaceuticals, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma, Eurofarma Laboratórios

Contents of the report:
1. Executive Summary
2. Filgrastim Biosimilars Market Report Structure
3. Filgrastim Biosimilars Market Trends And Strategies
4. Filgrastim Biosimilars Market - Macro Economic Scenario
5. Filgrastim Biosimilars Market Size And Growth
…..
27. Filgrastim Biosimilars Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Filgrastim Biosimilars Global Market to Observe Highest Growth of $1.66 Billion with an Excellent CAGR of 10.7% by 2028 | Sandoz Pty Ltd., Apotex Pty Ltd., Mylan, Lupin Limited, Biocon Biologics here

News-ID: 3587006 • Views:

More Releases from The Business research company

Company Registration Service Market Landscape 2025: Forecast Data and Growth Strategy Insights
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Company Registration Service Market Through 2025? The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecasts, and Growth Drivers
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025? In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market in 2025: Advancement In Digital Insurance Platforms Transforms Small And Medium Enterprises Coverage With Integrated, Data-Driven Solutions
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025? The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due To Rising Environmental Monitoring Requirements: Strengthening the Growth Trajectory of the Combustion Emissions Analyzer Market
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025? In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth

All 5 Releases


More Releases for Filgrastim

Filgrastim Injection Market Is Booming So Rapidly with Amgen, Sandoz, Teva Pharm …
HTF Market Insights just released the Global Filgrastim Injection Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach. Major companies Filgrastim Injection Market are: Amgen, Sandoz, Teva Pharmaceutical,
2024 Filgrastim Biosimilars Market: Size, Growth, Share, Trends, Forecast To 203 …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Filgrastim Biosimilars Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $1.66 billion In 2028 At
Filgrastim Biosimilars Global Market Analysis, Trends, Growth, Research And Fore …
The filgrastim biosimilars market size has grown strongly in recent years. It will grow from $1.02 billion in 2023 to $1.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to emerging markets growth, increase in patent expiration, government initiatives, increased healthcare expenditure, low cost of biosimilars, strong pipeline of drugs and increase in biopharmaceutical r&d
Filgrastim Biosimilars Market Size, Share And Trends Analysis Report 2024-2033
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033 The Business Research Company presents an extensive market research report on the Filgrastim Biosimilars Global Market Report 2024, furnishing businesses with a competitive edge through a detailed examination of the market structure, encompassing estimates for various segments and sub-segments. Furthermore, the report highlights on emerging trends, significant drivers, challenges, and opportunities,
Filgrastim Market Is Likely to Experience a Tremendous Growth by 2029
Filgrastim Market was valued at USD 992.8 million in 2022 and is expected to grow at a CAGR of 8% between 2023 and 2029. Filgrastim Market research involves carrying out thorough research on market to help newly emerging players in making calculated decision regarding which business ideas to follow. It is carried out to assess the viability of novel product or service. There are a few important goals can be
Filgrastim Market Report, History and Forecast 2023-2031
The report extensively examines the global Filgrastim market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Filgrastim. For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market for Filgrastim. We